Stay updated on Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.

Latest updates to the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page
- Check6 days agoChange DetectedThe study record for the Phase 3 PALOMA-3 trial is displayed, with details on eligibility, study locations, outcomes, and the comparison of subcutaneous versus intravenous amivantamab with lazertinib. The record also includes posted results and study documents.SummaryDifference100%

- Check13 days agoChange DetectedThe site footer’s displayed revision changes from v3.7.2 to v3.8.0 while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedA sitewide NIH notice about a terminology transition appears above the ClinicalTrials.gov 403 error page, and the site revision advances from v3.7.1 to v3.7.2.SummaryDifference1%

- Check41 days agoChange DetectedThe site revision identifier in the footer changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check55 days agoChange DetectedThe study page now displays a 403 Forbidden error with a Home link, replacing the previously loaded study content and related links. This indicates the page is currently inaccessible rather than showing study details.SummaryDifference16%

- Check62 days agoChange DetectedA new page revision, v3.7.0, has been published, replacing the previous v3.6.6. This reflects an update to the page's revision history rather than a change to substantive content.SummaryDifference0.0%

Stay in the know with updates to Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.